BRPI1006104A2 - gene que codifica glucoquinase humana mutante, glucoquinase humana mutante, vetor recombinante, hospedeiro, composicao farmaceutica, uso de um gene, de uma glucoquinase humana mutante, de um vetor recombinante, de um hospedeiro e de uma composição farmacêutica - Google Patents

gene que codifica glucoquinase humana mutante, glucoquinase humana mutante, vetor recombinante, hospedeiro, composicao farmaceutica, uso de um gene, de uma glucoquinase humana mutante, de um vetor recombinante, de um hospedeiro e de uma composição farmacêutica

Info

Publication number
BRPI1006104A2
BRPI1006104A2 BRPI1006104A BRPI1006104A BRPI1006104A2 BR PI1006104 A2 BRPI1006104 A2 BR PI1006104A2 BR PI1006104 A BRPI1006104 A BR PI1006104A BR PI1006104 A BRPI1006104 A BR PI1006104A BR PI1006104 A2 BRPI1006104 A2 BR PI1006104A2
Authority
BR
Brazil
Prior art keywords
mutant human
human glucokinase
host
pharmaceutical composition
recombinant vector
Prior art date
Application number
BRPI1006104A
Other languages
English (en)
Inventor
Haidong Huang
Original Assignee
Haidong Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haidong Huang filed Critical Haidong Huang
Publication of BRPI1006104A2 publication Critical patent/BRPI1006104A2/pt
Publication of BRPI1006104B1 publication Critical patent/BRPI1006104B1/pt
Publication of BRPI1006104B8 publication Critical patent/BRPI1006104B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI1006104A 2009-01-07 2010-01-06 gene isolado que codifica glucoquinase humana, vetor recombinante, hospedeiro, e, composição farmacêutica BRPI1006104B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910000087.1 2009-01-07
CN200910000087 2009-01-07
PCT/CN2010/070038 WO2010078842A1 (zh) 2009-01-07 2010-01-06 人葡萄糖激酶突变体编码基因、其编码的酶、重组载体及宿主、其药物组合物、应用以及预防和治疗疾病的方法

Publications (3)

Publication Number Publication Date
BRPI1006104A2 true BRPI1006104A2 (pt) 2016-02-16
BRPI1006104B1 BRPI1006104B1 (pt) 2021-04-20
BRPI1006104B8 BRPI1006104B8 (pt) 2021-05-25

Family

ID=42316263

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006104A BRPI1006104B8 (pt) 2009-01-07 2010-01-06 gene isolado que codifica glucoquinase humana, vetor recombinante, hospedeiro, e, composição farmacêutica

Country Status (21)

Country Link
US (1) US9029142B2 (pt)
EP (1) EP2388317B1 (pt)
JP (1) JP5721637B2 (pt)
KR (1) KR101300540B1 (pt)
CN (1) CN102272296B (pt)
AP (1) AP3277A (pt)
AU (1) AU2010204379B2 (pt)
BR (1) BRPI1006104B8 (pt)
CA (1) CA2749180C (pt)
DK (1) DK2388317T3 (pt)
EA (1) EA024878B1 (pt)
ES (1) ES2649021T3 (pt)
HU (1) HUE035110T2 (pt)
IL (1) IL213750A (pt)
MA (1) MA33034B1 (pt)
MX (1) MX2011007263A (pt)
NZ (1) NZ593893A (pt)
PT (1) PT2388317T (pt)
SG (1) SG172851A1 (pt)
WO (1) WO2010078842A1 (pt)
ZA (1) ZA201105209B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172244A1 (en) 2008-12-29 2011-07-28 Tel Hashomer Medical Res Infrastructure & Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
MX2011007263A (es) 2009-01-07 2011-10-06 Haidong Huang Gen que codifica para mutante de glucocinasa humana, enzima codificada por el mismo, vectores y hospederos recombinantes, composiciones farmaceuticas y usos de los mismos, y métodos para tratar y prevenir enfermedades.
WO2013117776A1 (es) * 2012-02-08 2013-08-15 Fundación Pública Andaluza Progreso Y Salud Enzimas glucocinasas con actividad aumentada y su uso en el tratamiento y/o prevención de la diabetes mellitus
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
JP6989262B2 (ja) 2014-10-27 2022-01-05 アセコー インコーポレイテッド 皮下外来患者管理
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3337402B1 (en) 2015-08-20 2026-01-07 Glytec, LLC Diabetes management therapy advisor
CN110564777B (zh) * 2019-09-23 2021-09-10 北京希诺谷生物科技有限公司 糖尿病疾病模型犬的建立方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
ES2170720B1 (es) * 2000-12-20 2003-12-16 Univ Barcelona Autonoma Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
US20070219346A1 (en) * 2002-04-22 2007-09-20 Mcgill University Glucose sensor and uses thereof
WO2005052132A2 (en) * 2003-11-24 2005-06-09 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
GB0423173D0 (en) * 2004-10-19 2004-11-24 Univ Newcastle Treatment of diabetes
US20070020237A1 (en) * 2005-06-01 2007-01-25 Biotech Institute For International Innovation, Inc. Glucose inducible insulin expression and methods of treating diabetes
DK2185696T3 (en) * 2007-08-10 2015-10-26 Univ Sydney Tech Cells genetically modified to include pancreatic glucokinase, and uses thereof
MX2011007263A (es) 2009-01-07 2011-10-06 Haidong Huang Gen que codifica para mutante de glucocinasa humana, enzima codificada por el mismo, vectores y hospederos recombinantes, composiciones farmaceuticas y usos de los mismos, y métodos para tratar y prevenir enfermedades.

Also Published As

Publication number Publication date
EP2388317B1 (en) 2017-08-30
MX2011007263A (es) 2011-10-06
AU2010204379B2 (en) 2014-02-13
CA2749180A1 (en) 2010-07-15
BRPI1006104B8 (pt) 2021-05-25
KR20110099057A (ko) 2011-09-05
KR101300540B1 (ko) 2013-09-02
WO2010078842A1 (zh) 2010-07-15
CN102272296B (zh) 2012-10-24
EA201170917A1 (ru) 2011-12-30
AP3277A (en) 2015-05-31
MA33034B1 (fr) 2012-02-01
HUE035110T2 (en) 2018-05-02
AP2011005814A0 (en) 2011-08-31
US20110286984A1 (en) 2011-11-24
SG172851A1 (en) 2011-08-29
US9029142B2 (en) 2015-05-12
IL213750A0 (en) 2011-07-31
NZ593893A (en) 2013-02-22
JP2012514463A (ja) 2012-06-28
CN102272296A (zh) 2011-12-07
ES2649021T3 (es) 2018-01-09
PT2388317T (pt) 2017-11-27
CA2749180C (en) 2017-03-21
ZA201105209B (en) 2012-09-26
EA024878B1 (ru) 2016-10-31
EP2388317A1 (en) 2011-11-23
IL213750A (en) 2015-11-30
DK2388317T3 (da) 2017-11-27
JP5721637B2 (ja) 2015-05-20
AU2010204379A1 (en) 2011-07-28
BRPI1006104B1 (pt) 2021-04-20
EP2388317A4 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
HRP20190137T1 (hr) Stabilne formulacije polipeptida i njihova uporaba
BRPI1005931A2 (pt) associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI1014316A2 (pt) composição, e, uso de uma composição
IL214822A0 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
ZA201200239B (en) Derivative of glp-1 analogue or its pharmaceutical salts and their use
BR112013015816A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina e uso de uma construção de dna
BR112013001571A2 (pt) composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI1006953A2 (pt) composição farmacêutica, e, uso de uma composição
BRPI1008039A2 (pt) composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
BRPI0816330A2 (pt) Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
PT2173868E (pt) Preparação recombinante de porções de bromelaína seleccionadas
BR112013011152A2 (pt) proteína beta-glucocerebrosidase recombinante variante, composição e uso da proteína betaglucocerebrosidase recombinante variante
BR112013030396A2 (pt) polipeptídeo, polinucleotídeo, vetor, célula hospedeira, composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina
HUE050793T2 (hu) Rekombináns HCG-t tartalmazó gyógyászati készítmény
BR112013015819A2 (pt) construção de dna, composição farmacêutica e uso de uma construção de dna
BRPI1008887A2 (pt) peptídeos de foxm1 e vacinas contendo os mesmo
BRPI1006666A2 (pt) " composição farmacêutica e uso de uma composição farmacêutica"
DK2388317T3 (da) Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom
IL219155A0 (en) Pharmaceutical formulations of nitrite and uses thereof
ZA201204619B (en) Pharmaceutical composition comprising vitamin d analogue and cosolventsurfactant mixture
BR112012011770A2 (pt) inalador para uma formulação de inalação e uso de um inalador para formulação de inalação
BR112012016736A2 (pt) composição , formulação farmacêutica e uso da composição"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/01/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2861 DE 04-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.